{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:41:07Z","timestamp":1693550467972},"reference-count":35,"publisher":"Wiley","issue":"4-5","license":[{"start":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T00:00:00Z","timestamp":1172793600000},"content-version":"vor","delay-in-days":5723,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[1991,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ifosfamide (1\u00b725 g\/m<jats:sup>2<\/jats:sup> intravenously\/day \u00d7 5) with mesna (20 per cent of the ifosfamide dose \u00d7 six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non\u2010Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29 per cent response rate (9\/31) was observed (two CR and seven PR) with a median duration of response of 2\u00b75 months. Myelosuppression was dose\u2010limiting. Hemorrhagic cystitis was observed in three patients (10 per cent). Nausea and vomiting was generally mild or moderate. One patient developed transient neurotoxic symptoms with confusion and disorientation. An additional patient developed an anaphylactic\u2010type reaction with shortness of breath and respiratory stridor during the fourth course of therapy. Ifosfamide, as a single agent, produces remissions of limited duration in non\u2010Hodgkin's lymphoma in patients in second or third relapse.<\/jats:p>","DOI":"10.1002\/hon.2900090404","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T19:01:21Z","timestamp":1171911681000},"page":"189-196","source":"Crossref","is-referenced-by-count":4,"title":["Phase II trial of ifosfamide and mesna in previously treated patients with non\u2010hodgkin's lymphoma: Cancer and leukemia group b study 8552"],"prefix":"10.1002","volume":"9","author":[{"suffix":"JR","given":"Delvyn C.","family":"Case","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Ervin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlan","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,6]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"451","article-title":"Studies on the human pharmacokinetics of isophosphamide (NSC\u2010109724)","volume":"60","author":"Allen L. M.","year":"1976","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(85)90011-8"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1139\/y83-001"},{"key":"e_1_2_1_5_1","unstructured":"Brock N.(1971).Pharmacological studies with ifosfamide\u2013a new oxazaphosphorine compound. Proceedings of the 7th International Congress of chemotherapy Prague 1971. In: Semonsky M. Hejzler M. Masak S. eds.Advances in Antimicrobial and Antineoplastic Chemotherapy Vol. 2 Baltimore: University Park Press 749\u2013756."},{"key":"e_1_2_1_6_1","first-page":"659","article-title":"Acrolein, the causative factor of urotoxic side\u2010effects of cyclophosphamide, ifosfamide, trofosfamide, and sufosfamide","volume":"29","author":"Brock N.","year":"1979","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-5379(81)80019-3"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(82)90143-2"},{"key":"e_1_2_1_9_1","unstructured":"Cabanillas F.(1982).AMSA in the treatment of recurrent lymphomas. Proceedings International Conference on AMSA."},{"key":"e_1_2_1_10_1","first-page":"933","article-title":"Ifosfamide, Methotrexate and Vincristine (IMV) combination chemotherapy as secondary treatment for patients with malignant lymphoma","volume":"64","author":"Cabanillas F.","year":"1980","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_11_1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood.V60.3.693.693","article-title":"IMVP\u201016 an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy","volume":"60","author":"Cabanillas F.","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.3.407"},{"key":"e_1_2_1_13_1","first-page":"751","article-title":"Phase I clinical trial of isophosphamide (NSC\u2010109724)","volume":"59","author":"Cohen M. H.","year":"1975","journal-title":"Cancer Chemother. Rep."},{"issue":"1","key":"e_1_2_1_14_1","first-page":"2","article-title":"The comparative pharmacology of cyclophosphamide and ifosfamide","volume":"9","author":"Colvin M.","year":"1982","journal-title":"Semin. Oncol."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(79)90222-3"},{"key":"e_1_2_1_16_1","first-page":"115","article-title":"Studies on the clinical pharmacology and toxicology of isophosphamide","volume":"60","author":"Creaven P. J.","year":"1976","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1108490"},{"key":"e_1_2_1_18_1","first-page":"225","article-title":"Treatment of relapsed non\u2010Hodgkin's lymphoma with a combination of hydroxyurea, ifosfamide, and etoposide","volume":"69","author":"Gasser A. B.","year":"1985","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_19_1","first-page":"127","article-title":"Ifosfamide\u2010induced subclinical tubular nephrotoxicity despite mesna","volume":"71","author":"Goren M. P.","year":"1987","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00405909"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(83)80027-9"},{"issue":"1","key":"e_1_2_1_22_1","first-page":"78","article-title":"Use and safety of high\u2010dose ifosfamide","volume":"9","author":"Holoye P. Y.","year":"1982","journal-title":"Semin. Oncol."},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830901)52:5<833::AID-CNCR2820520515>3.0.CO;2-R"},{"key":"e_1_2_1_24_1","first-page":"85","article-title":"Metabolism and metabolic effects of alcohol","volume":"17","author":"Lieber C. S.","year":"1980","journal-title":"Seprin. Hematol."},{"key":"e_1_2_1_25_1","first-page":"919","article-title":"Ifosfamide plus N\u2010acetylcystein in the treatment of small cell and non\u2010small cell carcinoma of the lung: A Southeastern Cancer Study Group Trial","volume":"70","author":"Loehrer P. J.","year":"1986","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_26_1","first-page":"437","article-title":"Studies on the metabolism of ifosfamide (NSC\u2010109724) in man","volume":"60","author":"Norpoth K.","year":"1976","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00263897"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1253"},{"key":"e_1_2_1_29_1","first-page":"131","article-title":"Phase II trial of ifosfamide in children with malignant solid tumors","volume":"71","author":"Pratt C. B.","year":"1987","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_30_1","volume-title":"Atlas of Tumour Pathology","author":"Rappaport H.","year":"1966"},{"key":"e_1_2_1_31_1","first-page":"2945","article-title":"Reduction of ifosfamide toxicity using dose fractionation","volume":"36","author":"Rodriguez V.","year":"1976","journal-title":"Cancer Res."},{"key":"e_1_2_1_32_1","first-page":"493","article-title":"Ifosfamide therapy for hematologic malignancies in patients refractory to prior treatment","volume":"62","author":"Rodriguez V.","year":"1978","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_33_1","first-page":"501","article-title":"Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines, preliminary results","volume":"63","author":"Scheef W.","year":"1979","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(83)80019-X"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-6525-3_5"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.1.28"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2900090404","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2900090404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T07:16:58Z","timestamp":1693466218000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2900090404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,7]]},"references-count":35,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[1991,7]]}},"alternative-id":["10.1002\/hon.2900090404"],"URL":"https:\/\/doi.org\/10.1002\/hon.2900090404","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,7]]}}}